About
By understanding a virus’ evolutionary trajectory in advance, we can build prospective vaccines.
What if we could engineer prospective vaccines to elicit ideal immune responses against present and emerging health threats, a priori?
By the time we design, manufacture and approve vaccines, many viruses have already evolved, making it hard to keep pace and fight back.
Our pioneering approach to vaccinology centers on a unique platform, Octavia™, that combines biological insights with advanced AI/ML to harness the power of prediction. Our Octavia platform predicts viral evolution, delivers improved vaccines, and assesses how well they will perform before entering clinical trials.
Apriori was founded in 2020 by Flagship Pioneering.
